JP2019085423A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019085423A5 JP2019085423A5 JP2019044231A JP2019044231A JP2019085423A5 JP 2019085423 A5 JP2019085423 A5 JP 2019085423A5 JP 2019044231 A JP2019044231 A JP 2019044231A JP 2019044231 A JP2019044231 A JP 2019044231A JP 2019085423 A5 JP2019085423 A5 JP 2019085423A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- ear
- release
- examples
- penetration enhancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 description 29
- 238000009472 formulation Methods 0.000 description 24
- 239000003961 penetration enhancing agent Substances 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000000499 gel Substances 0.000 description 8
- 239000003623 enhancer Substances 0.000 description 6
- 239000002502 liposome Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 239000013543 active substance Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000013270 controlled release Methods 0.000 description 4
- 238000012377 drug delivery Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000003232 mucoadhesive effect Effects 0.000 description 4
- 239000000017 hydrogel Substances 0.000 description 3
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- -1 alkyl glucoside Chemical class 0.000 description 2
- 230000002902 bimodal effect Effects 0.000 description 2
- 210000000959 ear middle Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 229920000428 triblock copolymer Polymers 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- QGLWBTPVKHMVHM-KTKRTIGZSA-N (z)-octadec-9-en-1-amine Chemical compound CCCCCCCC\C=C/CCCCCCCCN QGLWBTPVKHMVHM-KTKRTIGZSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical class CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 235000021319 Palmitoleic acid Nutrition 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 210000003027 ear inner Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 235000012209 glucono delta-lactone Nutrition 0.000 description 1
- 229960003681 gluconolactone Drugs 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 229940125703 otic agent Drugs 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 210000003454 tympanic membrane Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (42)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4654308P | 2008-04-21 | 2008-04-21 | |
| US61/046,543 | 2008-04-21 | ||
| US4887808P | 2008-04-29 | 2008-04-29 | |
| US61/048,878 | 2008-04-29 | ||
| US12771308P | 2008-05-14 | 2008-05-14 | |
| US61/127,713 | 2008-05-14 | ||
| US5562508P | 2008-05-23 | 2008-05-23 | |
| US61/055,625 | 2008-05-23 | ||
| US6042508P | 2008-06-10 | 2008-06-10 | |
| US61/060,425 | 2008-06-10 | ||
| US7371608P | 2008-06-18 | 2008-06-18 | |
| US61/073,716 | 2008-06-18 | ||
| US7458308P | 2008-06-20 | 2008-06-20 | |
| US61/074,583 | 2008-06-20 | ||
| US7656708P | 2008-06-27 | 2008-06-27 | |
| US7657608P | 2008-06-27 | 2008-06-27 | |
| US61/076,567 | 2008-06-27 | ||
| US61/076,576 | 2008-06-27 | ||
| US8245008P | 2008-07-21 | 2008-07-21 | |
| US61/082,450 | 2008-07-21 | ||
| US8383008P | 2008-07-25 | 2008-07-25 | |
| US8387108P | 2008-07-25 | 2008-07-25 | |
| US61/083,871 | 2008-07-25 | ||
| US61/083,830 | 2008-07-25 | ||
| US8609408P | 2008-08-04 | 2008-08-04 | |
| US8610508P | 2008-08-04 | 2008-08-04 | |
| US61/086,105 | 2008-08-04 | ||
| US61/086,094 | 2008-08-04 | ||
| US8795108P | 2008-08-11 | 2008-08-11 | |
| US8790508P | 2008-08-11 | 2008-08-11 | |
| US61/087,951 | 2008-08-11 | ||
| US61/087,905 | 2008-08-11 | ||
| US8827508P | 2008-08-12 | 2008-08-12 | |
| US61/088,275 | 2008-08-12 | ||
| US9438408P | 2008-09-04 | 2008-09-04 | |
| US61/094,384 | 2008-09-04 | ||
| US10111208P | 2008-09-29 | 2008-09-29 | |
| US61/101,112 | 2008-09-29 | ||
| US14003308P | 2008-12-22 | 2008-12-22 | |
| US61/140,033 | 2008-12-22 | ||
| US16023309P | 2009-03-13 | 2009-03-13 | |
| US61/160,233 | 2009-03-13 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017076319A Division JP6544535B2 (ja) | 2008-04-21 | 2017-04-06 | 耳の疾患と疾病を処置するための耳の製剤と関連する応用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020106530A Division JP2020147610A (ja) | 2008-04-21 | 2020-06-19 | 耳の疾患と疾病を処置するための耳の製剤と関連する応用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019085423A JP2019085423A (ja) | 2019-06-06 |
| JP2019085423A5 true JP2019085423A5 (cg-RX-API-DMAC7.html) | 2019-09-05 |
Family
ID=41217397
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011505264A Pending JP2011518195A (ja) | 2008-04-21 | 2009-04-21 | 耳の疾患と疾病を処置するための耳の製剤と関連する応用 |
| JP2013251480A Expired - Fee Related JP6147653B2 (ja) | 2008-04-21 | 2013-12-04 | 耳の疾患と疾病を処置するための耳の製剤と関連する応用 |
| JP2015217021A Expired - Fee Related JP6296565B2 (ja) | 2008-04-21 | 2015-11-04 | 耳の疾患と疾病を処置するための耳の製剤と関連する応用 |
| JP2017076319A Active JP6544535B2 (ja) | 2008-04-21 | 2017-04-06 | 耳の疾患と疾病を処置するための耳の製剤と関連する応用 |
| JP2019044231A Pending JP2019085423A (ja) | 2008-04-21 | 2019-03-11 | 耳の疾患と疾病を処置するための耳の製剤と関連する応用 |
| JP2020106530A Pending JP2020147610A (ja) | 2008-04-21 | 2020-06-19 | 耳の疾患と疾病を処置するための耳の製剤と関連する応用 |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011505264A Pending JP2011518195A (ja) | 2008-04-21 | 2009-04-21 | 耳の疾患と疾病を処置するための耳の製剤と関連する応用 |
| JP2013251480A Expired - Fee Related JP6147653B2 (ja) | 2008-04-21 | 2013-12-04 | 耳の疾患と疾病を処置するための耳の製剤と関連する応用 |
| JP2015217021A Expired - Fee Related JP6296565B2 (ja) | 2008-04-21 | 2015-11-04 | 耳の疾患と疾病を処置するための耳の製剤と関連する応用 |
| JP2017076319A Active JP6544535B2 (ja) | 2008-04-21 | 2017-04-06 | 耳の疾患と疾病を処置するための耳の製剤と関連する応用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020106530A Pending JP2020147610A (ja) | 2008-04-21 | 2020-06-19 | 耳の疾患と疾病を処置するための耳の製剤と関連する応用 |
Country Status (13)
| Country | Link |
|---|---|
| US (8) | US9132087B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2278999B1 (cg-RX-API-DMAC7.html) |
| JP (6) | JP2011518195A (cg-RX-API-DMAC7.html) |
| KR (6) | KR20160029870A (cg-RX-API-DMAC7.html) |
| CN (2) | CN102014957B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2009239429B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0910850B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2721927C (cg-RX-API-DMAC7.html) |
| HK (1) | HK1209055A1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL208549A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2010011545A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2499592C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009132050A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (160)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008076556A2 (en) | 2006-11-15 | 2008-06-26 | Massachusetts Eye & Ear Infirmary | Generation of inner ear cells |
| US9994585B2 (en) | 2007-12-31 | 2018-06-12 | Aphios Corporation | Transplantation therapies |
| US11969501B2 (en) | 2008-04-21 | 2024-04-30 | Dompé Farmaceutici S.P.A. | Auris formulations for treating otic diseases and conditions |
| WO2009132050A2 (en) | 2008-04-21 | 2009-10-29 | Otonomy, Inc. | Auris formulations for treating otic diseases and conditions |
| MY161021A (en) | 2008-05-14 | 2017-03-31 | Otonomy Inc | Controlled release corticosteroid and methods for the treatment of otic disorders |
| US8846770B2 (en) | 2008-06-18 | 2014-09-30 | Otonomy, Inc. | Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders |
| GB2461962B (en) * | 2008-07-25 | 2011-02-16 | Otonomy Inc | Slow release NMDA receptor antagonist for otic disorders |
| WO2010011466A2 (en) | 2008-06-27 | 2010-01-28 | Otonomy, Inc. | Controlled-release cns modulating compositions and methods for the treatment of otic disorders |
| US8318817B2 (en) | 2008-07-21 | 2012-11-27 | Otonomy, Inc. | Controlled release antimicrobial compositions and methods for the treatment of otic disorders |
| US8496957B2 (en) | 2008-07-21 | 2013-07-30 | Otonomy, Inc | Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders |
| US8784870B2 (en) * | 2008-07-21 | 2014-07-22 | Otonomy, Inc. | Controlled release compositions for modulating free-radical induced damage and methods of use thereof |
| CN102159209A (zh) * | 2008-08-11 | 2011-08-17 | 奥克兰联合服务有限公司 | 听力缺失的治疗 |
| CA2751761A1 (en) | 2008-10-22 | 2010-04-29 | House Ear Institute | Treatment and/or prevention of inner ear conditions by modulation of a metabotropic glutamate receptor |
| US8987328B2 (en) * | 2008-10-30 | 2015-03-24 | Trinity Laboratories, Inc. | Esters of capsaicinoids as dietary supplements |
| WO2010060088A2 (en) | 2008-11-24 | 2010-05-27 | Massachusetts Eye & Ear Infirmary | Pathways to generate hair cells |
| CN106344495A (zh) * | 2008-12-22 | 2017-01-25 | 奥德纳米有限公司 | 用于治疗耳部病症的控制释放耳感觉细胞调节剂组合物 |
| EP2437772B1 (en) | 2009-06-05 | 2017-12-06 | 13Therapeutics, Inc. | Immunoregulatory peptides and methods of use |
| CA2772097C (en) | 2009-08-24 | 2019-04-30 | Hough Ear Institute | Methods for treating acute acoustic trauma |
| WO2011025771A1 (en) * | 2009-08-25 | 2011-03-03 | Biogen Idec Ma Inc. | Compositions for delivery of insoluble agents |
| US20140076336A1 (en) * | 2009-09-17 | 2014-03-20 | Ascentia Health, Inc. | Ear insert for relief of tmj discomfort and headaches |
| WO2011049958A2 (en) * | 2009-10-21 | 2011-04-28 | Otonomy, Inc. | Modulation of gel temperature of poloxamer-containing formulations |
| CN102008470B (zh) * | 2010-05-24 | 2012-08-29 | 中国人民解放军第二军医大学 | 复方制剂及其预防和治疗噪声性听力损伤的用途 |
| WO2011150859A1 (en) * | 2010-06-04 | 2011-12-08 | Comprehensive Drug Enterprises Ltd | Oral meclizine aqueous formulations with taste flavoring agent |
| WO2011156631A2 (en) * | 2010-06-09 | 2011-12-15 | Joule Unlimited Technologies, Inc. | Methods and compositions to extract carbon-based products from host cells |
| DE102010030053A1 (de) * | 2010-06-14 | 2011-12-15 | Awd.Pharma Gmbh & Co.Kg | Injizierbare Darreichungsform von Flupirtin |
| WO2011157449A1 (en) * | 2010-06-18 | 2011-12-22 | Merz Pharma Gmbh & Co. Kgaa | Gel formulations for the topical use of 1-amino-alkylcyclohexane derivatives |
| KR101134622B1 (ko) * | 2010-08-12 | 2012-04-09 | 한국원자력연구원 | 암포테리신 b의 서방성 수화겔 및 이의 제조방법 |
| WO2012037117A1 (en) | 2010-09-13 | 2012-03-22 | Bev-Rx, Inc. | Aqueous drug delivery system comprising off - flavor masking agent |
| EP3501521A1 (en) * | 2011-02-18 | 2019-06-26 | Otonomy, Inc. | Prevention of and recovery from drug-induced ototoxicity |
| JP2014507441A (ja) * | 2011-02-25 | 2014-03-27 | エイド・ファルマ | 単独で、または抗生物質と共に感染症を予防または治療するための精油のナノカプセル化 |
| US8580748B2 (en) * | 2011-04-06 | 2013-11-12 | 13Therapeutics, Inc. | Peptides for the treatment of hearing |
| CN102805896A (zh) * | 2011-05-30 | 2012-12-05 | 惠觅宙 | 经皮给药方法、制剂和系统 |
| US9193704B2 (en) * | 2011-06-07 | 2015-11-24 | Autifony Therapeutics Limited | Hydantoin derivatives as KV3 inhibitors |
| US9901616B2 (en) | 2011-08-31 | 2018-02-27 | University Of Georgia Research Foundation, Inc. | Apoptosis-targeting nanoparticles |
| RU2480214C1 (ru) | 2011-09-22 | 2013-04-27 | Валентина Ивановна Ахапкина | Состав, обладающий модуляторной активностью с соразмерным влиянием, фармацевтическая субстанция (варианты), применение фармацевтической субстанции, фармацевтическая и парафармацевтическая композиция (варианты), способ получения фармацевтических составов |
| US20140341940A1 (en) * | 2011-11-09 | 2014-11-20 | Iseu da Silva Nunes | Immunomodulator for the treatment of cancerous tumors in the epithelial tissue lining surfaces inside or outside body organs |
| WO2013090452A1 (en) | 2011-12-12 | 2013-06-20 | Orbis Biosciences, Inc. | Sustained release particle formulations |
| US9034347B2 (en) * | 2011-12-19 | 2015-05-19 | Arphios Corporation | Drug delivery system and method for the treatment of neuro-degenerative disease |
| US10416167B2 (en) | 2012-02-17 | 2019-09-17 | University Of Georgia Research Foundation, Inc. | Nanoparticles for mitochondrial trafficking of agents |
| WO2013124416A1 (en) * | 2012-02-23 | 2013-08-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Calcineurin inhibitors for use in the treatment of lesional vestibular disorders |
| EP2819741B1 (en) * | 2012-02-27 | 2018-03-28 | O-Ray Pharma, Inc. | Solid drug implants for intracochlear delivery of therapeutics for the treatment of otic disorders |
| US20130288981A1 (en) * | 2012-04-02 | 2013-10-31 | Buck Institute For Research On Aging | Targeting senescent cells and cancer cells by interference with jnk and/or foxo4 |
| EP2872128B1 (en) * | 2012-07-16 | 2020-02-19 | Cornell University | Nicotinamide riboside to treat hearing loss |
| EP2892506B1 (en) | 2012-09-07 | 2021-11-03 | Massachusetts Eye & Ear Infirmary | Treating hearing loss with the gamma-secretase inhibitor ly411575 |
| JP6579956B2 (ja) | 2012-11-28 | 2019-09-25 | アフィオス コーポレーション | 神経変性疾患および他の疾患の治療のための併用治療薬および方法 |
| BR112015023261A2 (pt) | 2013-03-14 | 2017-07-18 | Massachusetts Inst Technology | composições e métodos para expansão e cultura de células-tronco epiteliais |
| WO2014178892A1 (en) | 2013-05-03 | 2014-11-06 | Scanlan Thomas S | Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy |
| CN110420316A (zh) | 2013-06-18 | 2019-11-08 | 纽约大学 | 参与金黄色葡萄球菌杀白细胞素的细胞毒性的细胞因素:新型治疗靶点 |
| CN105682742A (zh) | 2013-08-27 | 2016-06-15 | 奥德纳米有限公司 | 小儿耳部病症的治疗 |
| EP2853533A1 (de) * | 2013-09-29 | 2015-04-01 | Audiocure Pharma GmbH | 6-Fluor-9-methyl-ß-carbolin |
| RU2551359C9 (ru) * | 2013-11-28 | 2021-08-20 | Общество с ограниченной ответственностью "Мамонт Фарм" | Наноразмерная слабо закристаллизованная модификация 4-метил-N-[3-(4-метилимидазол-1-ил)-5-(трифторметил)фенил]-3-[(4-пиридин-3-илпиримидин-2-ил)амино]бензамида гидрохлорида моногидрата, способ ее получения и фармацевтическая композиция на ее основе |
| WO2015126192A1 (ko) * | 2014-02-20 | 2015-08-27 | 아주대학교산학협력단 | 시스테인 류코트리엔 수용체 길항제 및 은행잎 추출물을 포함하는 감각신경성 난청의 치료 또는 예방용 약학 조성물 |
| WO2015138992A1 (en) | 2014-03-14 | 2015-09-17 | University Of Georgia Research Foundation, Inc. | Mitochondrial delivery of 3-bromopyruvate |
| EP3139744A4 (en) * | 2014-04-23 | 2017-12-20 | Auris Medical AG | Methods and compositions for treating and preventing tinnitus |
| US10010585B2 (en) * | 2014-06-16 | 2018-07-03 | Massachusetts Eye And Ear Infirmary | Methods of treating vestibular schwannoma and reducing hearing or neurite loss caused by vestibular schwannoma |
| WO2016022776A2 (en) | 2014-08-06 | 2016-02-11 | Massachusetts Eye And Ear Infirmary | Increasing atoh1 life to drive sensorineural hair cell differentiantion |
| CN107073042A (zh) * | 2014-09-03 | 2017-08-18 | 布里格海姆妇女医院公司 | 用于产生内耳毛细胞来治疗听力损失的组合物、系统和方法 |
| US10058542B1 (en) | 2014-09-12 | 2018-08-28 | Thioredoxin Systems Ab | Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith |
| TW201625232A (zh) * | 2014-10-01 | 2016-07-16 | 陳建宏 | 含有阿司匹靈、二甲雙胍和血清素與非離子界面活性劑的醫藥組合物 |
| DK3256850T3 (da) * | 2015-02-09 | 2025-08-18 | Slingshot Biosciences Inc | Hydrogelpartikler med justerbare optiske egenskaber og fremgangsmåder til anvendelse deraf |
| PE20180021A1 (es) | 2015-02-20 | 2018-01-09 | Univ Oregon Health & Science | Derivados de sobetiroma |
| KR101636733B1 (ko) * | 2015-02-24 | 2016-07-07 | 인제대학교 산학협력단 | 에키노크롬 a를 유효성분으로 함유하는 운동능력 증진용 건강식품 및 이를 이용한 운동능력 증진방법 |
| GB201505527D0 (en) | 2015-03-31 | 2015-05-13 | Jmedtech Pte Ltd | Composition |
| EP3328898B8 (en) * | 2015-07-28 | 2024-04-10 | 6452728 Canada Corp. | Trkb or trkc agonist compositions and methods for the treatment of otic conditions |
| MX388197B (es) * | 2015-08-21 | 2025-03-19 | Hoffmann La Roche | Método para la reducción de proteínas de células hospederas en cromatografía de afinidad. |
| EP3368553B1 (en) * | 2015-10-27 | 2023-08-02 | Purdue Research Foundation | Polymer-based therapeutics for inductive browning of fat |
| US20170128424A1 (en) * | 2015-11-11 | 2017-05-11 | Qrono, Inc. | Sustained release pharmaceutical compositions and methods of use |
| AU2016355236C1 (en) | 2015-11-16 | 2022-09-22 | Medincell | A method for morselizing and/or targeting pharmaceutically active principles to synovial tissue |
| WO2017096233A1 (en) | 2015-12-04 | 2017-06-08 | Massachusetts Eye And Ear Infirmary | Treatment of hearing loss by inhibition of casein kinase 1 |
| CA3010610A1 (en) | 2016-01-08 | 2017-07-13 | The Brigham And Women's Hospital, Inc. | Production of differentiated enteroendocrine cells and insulin producing cells |
| CN109219439B (zh) | 2016-01-29 | 2022-09-20 | 马萨诸塞眼科耳科诊所 | 内耳支持细胞的扩增和分化及其使用方法 |
| WO2017147221A1 (en) * | 2016-02-26 | 2017-08-31 | Med-El Elektromedizinische Geraete Gmbh | Detection of electrically evoked stapedius reflex |
| US11260130B2 (en) | 2016-03-02 | 2022-03-01 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV |
| US10201540B2 (en) | 2016-03-02 | 2019-02-12 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I |
| US10213511B2 (en) | 2016-03-02 | 2019-02-26 | Frequency Therapeutics, Inc. | Thermoreversible compositions for administration of therapeutic agents |
| KR101785455B1 (ko) * | 2016-03-16 | 2017-11-20 | 전남대학교산학협력단 | 귀리 추출물을 유효성분으로 포함하는 난청의 예방 또는 치료용 약제학적 조성물 |
| CN109310695B (zh) | 2016-04-21 | 2022-04-01 | 阿斯特罗赛特制药公司 | 治疗神经和心血管病况的化合物和方法 |
| EP3478269A4 (en) * | 2016-06-29 | 2020-04-08 | Otonomy, Inc. | OTIC FORMULATIONS BASED ON TRIGLYCERIDES AND THEIR USES |
| US20190254997A1 (en) * | 2016-07-21 | 2019-08-22 | The Regents Of The University Of California | Methods for inducing stereocilia on hair cells |
| EP3512513A4 (en) | 2016-09-16 | 2020-04-15 | Otonomy, Inc. | OTIC GEL FORMULATIONS FOR THE TREATMENT OF EXTERNAL OTITIS |
| US10707531B1 (en) | 2016-09-27 | 2020-07-07 | New Dominion Enterprises Inc. | All-inorganic solvents for electrolytes |
| US10576125B2 (en) | 2016-10-31 | 2020-03-03 | Hough Ear Institute | Methods for enhancing synaptogenesis and neuritogenesis |
| US11253193B2 (en) * | 2016-11-08 | 2022-02-22 | Cochlear Limited | Utilization of vocal acoustic biomarkers for assistive listening device utilization |
| WO2018094262A2 (en) * | 2016-11-18 | 2018-05-24 | Mayo Foundation For Medical Education And Research | Materials and methods for treating regional pain |
| EP3554487A4 (en) * | 2016-12-13 | 2020-10-21 | The Regents of The University of California | XENOBIOTIC FREE CULTURE SYSTEM TO GROW HUMAN LIMBIC STEM CELLS |
| RU2630129C1 (ru) * | 2016-12-19 | 2017-09-05 | Государственное бюджетное учреждение здравоохранения города Москвы "Научно-исследовательский клинический институт оториноларингологии им. Л.И. Свержевского" Департамента здравоохранения города Москвы | Способ определения степени эндолимфатического гидропса при болезни меньера, выбор тактики лечения и оценка ее эффективности |
| AU2017386417B2 (en) | 2016-12-30 | 2022-07-14 | Frequency Therapeutics, Inc. | 1H-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells |
| DK3698791T3 (da) * | 2017-02-02 | 2024-01-15 | Otolanum Ag | Intranasal sammensætning, der omfatter betahistin |
| JP7167059B2 (ja) * | 2017-04-19 | 2022-11-08 | フィオ ファーマシューティカルズ コーポレーション | 核酸化合物の局所送達 |
| US12076415B2 (en) | 2017-08-18 | 2024-09-03 | King Fahd University Of Petroleum And Minerals | Use of nano-sized clay crystallites to restore adhesion among tumor and aging stem cells |
| EP3691618A1 (en) | 2017-10-06 | 2020-08-12 | Foundry Therapeutics, Inc. | Implantable depots for the controlled release of therapeutic agents |
| WO2019118330A1 (en) * | 2017-12-12 | 2019-06-20 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Thermoresponsive hydrogel containing polymer microparticles for controlled drug delivery to the ear |
| US11918653B2 (en) * | 2017-12-22 | 2024-03-05 | Dompé Farmaceutici S.P.A. | Triglyceride otic formulations and uses thereof |
| CN116650732A (zh) | 2018-01-08 | 2023-08-29 | 铸造疗法股份有限公司 | 经由治疗剂的控制递送用于治疗腔内癌症的装置、系统和方法 |
| WO2019140012A1 (en) * | 2018-01-09 | 2019-07-18 | Otonomy, Inc. | Growth factor otic formulations |
| WO2019152110A1 (en) * | 2018-01-31 | 2019-08-08 | Kci Usa, Inc. | Antimicrobial composition, dressing, dressing components, and method |
| US11839615B2 (en) | 2018-02-09 | 2023-12-12 | Astrocyte Pharmaceuticals, Inc. | Compounds and methods for treating addiction and related disorders |
| BR112020016059A2 (pt) * | 2018-02-09 | 2020-12-08 | Decibel Therapeutics, Inc. | Composições farmacêuticas hipertônicas contendo um agente quimioprotetor anti-platina |
| JP6383133B1 (ja) * | 2018-02-21 | 2018-08-29 | 国立大学法人信州大学 | 液体塞栓剤組成物 |
| US20190307885A1 (en) * | 2018-04-04 | 2019-10-10 | Alivio Therapeutics, Inc. | Self-assembled gels for controlled delivery of biologics and methods of making thereof |
| US12458589B2 (en) | 2018-05-12 | 2025-11-04 | Foundry Therapeutics, Inc. | Implantable polymer depots for the controlled release of therapeutic agents |
| WO2020037323A1 (en) | 2018-08-17 | 2020-02-20 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by upregulating jag-1 |
| WO2020037326A1 (en) | 2018-08-17 | 2020-02-20 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by downregulating foxo |
| EP3843710A1 (en) | 2018-08-28 | 2021-07-07 | Foundry Therapeutics, Inc. | Polymer implants |
| KR102928295B1 (ko) | 2018-09-07 | 2026-02-13 | 알.피.쉐러 테크놀러지즈 엘엘씨 | 경화 및 낮은 hlb 계면 활성제(들)의 첨가를 통한 고체 또는 반고체 지질 기반 제형 안정화 |
| EP3856741A4 (en) | 2018-09-26 | 2022-06-22 | Astrocyte Pharmaceuticals, Inc. | POLYMORPHOUS COMPOUNDS AND USES THEREOF |
| EP3894383A1 (en) | 2018-12-12 | 2021-10-20 | Autobahn Therapeutics, Inc. | Novel thyromimetics |
| WO2020123866A1 (en) * | 2018-12-12 | 2020-06-18 | Curelator, Inc. | System and method for detecting auditory biomarkers |
| US10561736B1 (en) | 2019-01-09 | 2020-02-18 | Spiral Therapeutics, Inc. | Apoptosis inhibitor formulations for prevention of hearing loss |
| CA3130371A1 (en) | 2019-03-01 | 2020-09-10 | Autobahn Therapeutics, Inc. | Novel thyromimetics |
| EP3962533A4 (en) | 2019-04-30 | 2023-01-25 | The Medical College of Wisconsin, Inc. | PLATFORM FOR THROAT ADMINISTRATION AND USES THEREOF |
| CN114174799A (zh) * | 2019-05-30 | 2022-03-11 | 贝克曼库尔特有限公司 | 用于固定生物标本以进行显微成像的方法和系统 |
| CN110101871B (zh) * | 2019-05-30 | 2022-03-25 | 广东工业大学 | 一种包埋白藜芦醇的制备方法 |
| US10813947B1 (en) | 2019-05-31 | 2020-10-27 | Decibel Therapeutics, Inc. | Methods of otoprotection against platinum-based antineoplastic agents |
| WO2020254249A1 (en) * | 2019-06-21 | 2020-12-24 | Proqr Therapeutics Ii B.V. | Delivery of nucleic acids for the treatment of auditory disorders |
| AU2019467888B2 (en) * | 2019-09-24 | 2025-09-11 | Halliburton Energy Services, Inc. | Fragile and normal viscoelastic components of drilling fluid gels |
| WO2021092499A1 (en) * | 2019-11-08 | 2021-05-14 | Spiral Therapeautics, Inc. | Treatments of meniere's disease |
| CN115279359A (zh) | 2019-11-29 | 2022-11-01 | 速通医疗公司 | 新型拟甲状腺素药 |
| RU2749857C1 (ru) * | 2019-12-23 | 2021-06-17 | Псарева Нелли Александровна | Способ борьбы со средним и наружным отитом |
| BR112022013755A2 (pt) * | 2020-01-13 | 2022-10-11 | Astromedical Biotechnology Ltd | Métodos para o tratamento de caquexia e de câncer, e, composição farmacêutica |
| WO2021151013A1 (en) * | 2020-01-24 | 2021-07-29 | Otonomy, Inc. | Growth factor formulation for condition associated with otic event |
| CN115426991A (zh) | 2020-01-24 | 2022-12-02 | 斯皮拉尔诊疗有限公司 | 用于治疗耳部疾病的装置、系统和方法 |
| EP3854385A1 (en) | 2020-01-27 | 2021-07-28 | ROS Therapeutics ApS | Methotrexate dosage form |
| DK4114975T3 (da) * | 2020-03-06 | 2026-06-15 | Regeneron Pharma | Fascin-2 (fscn2) variant og anvendelse deraf |
| AU2021235058A1 (en) * | 2020-03-11 | 2022-09-01 | Iterum Therapeutics International Limited | Combinations of beta-lactam compounds, probenecid, and valproic acid and uses thereof |
| CA3177834A1 (en) | 2020-05-04 | 2021-11-11 | Jeffrey Kim | Compositions and methods for passive optical barcoding for multiplexed assays |
| NL2025530B1 (en) * | 2020-05-08 | 2021-11-23 | Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis | Fluid injection device |
| EP4149431A4 (en) * | 2020-05-13 | 2024-05-29 | Spiral Therapeutics Inc. | GELLING SOLUTIONS FOR DELIVERY OF COMPOUNDS TO THE INNER EAR |
| RU2741252C1 (ru) * | 2020-06-01 | 2021-01-22 | федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) (ФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России (Се | Способ выбора метода хирургического лечения пациентов с болезнью меньера |
| EP4167986A4 (en) | 2020-06-17 | 2024-11-20 | Autobahn Therapeutics, Inc. | THYROMIMETICS |
| EP4168384A4 (en) | 2020-06-17 | 2024-07-10 | Autobahn Therapeutics, Inc. | THYROMIMETICS |
| KR20240127867A (ko) * | 2020-08-10 | 2024-08-23 | 지로파, 인코포레이티드 | 국소 전달을 위한 조성물 및 방법 |
| CA3190833A1 (en) * | 2020-08-26 | 2022-03-03 | Michael Mcdonald CROWLEY | Compositions, devices and methods for treating nasal, otic and other tissue infection and/or inflammation |
| WO2022047234A1 (en) * | 2020-08-28 | 2022-03-03 | President And Fellows Of Harvard College | Drug combination kits and methods of drug delivery |
| RU2751697C1 (ru) * | 2020-09-09 | 2021-07-15 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Донской государственный аграрный университет" | Средство для лечения отитов наружного слухового прохода у собак |
| CN112618571B (zh) * | 2020-09-30 | 2023-04-07 | 杭州贤石生物科技有限公司 | 治疗骨科疾病的可注射水凝胶微球及其制备方法与应用 |
| CN112125969A (zh) * | 2020-09-30 | 2020-12-25 | 东南大学 | 生物因子rimbp2在维持内耳毛细胞特性上的应用 |
| EP4251127A1 (en) | 2020-11-26 | 2023-10-04 | Alain Moussy | Pharmaceutical composition for treatment of inner ear disorders through local administration in the tympanic area |
| CN112557158B (zh) * | 2021-02-28 | 2021-05-28 | 中国工程物理研究院核物理与化学研究所 | 一种用于空气样品中氙的分离纯化收集装置 |
| WO2022231076A1 (ko) * | 2021-04-30 | 2022-11-03 | 서울대학교병원 | 감각신경성 난청의 원인 특이적 치료 효과 예측 방법 및 이에 사용되는 진단 키트 |
| AU2022271304A1 (en) | 2021-05-06 | 2023-11-23 | Autobahn Therapeutics, Inc. | Fatty acid amide hydrolase (faah) cleavable prodrugs of thyromimetics and combination with peripherally restricted faah inhibitors |
| CN113425852B (zh) * | 2021-05-24 | 2022-06-03 | 北京大学 | 一种可穿过血迷路屏障的偶联物及其制备方法 |
| CN113456580B (zh) * | 2021-07-21 | 2024-03-22 | 沈阳化工大学 | 一种白藜芦醇原位凝胶制备及其表征方法 |
| KR102675908B1 (ko) | 2021-09-03 | 2024-06-14 | 충남대학교산학협력단 | 내이 질환 치료를 위한 국소 약물전달용 나노입자 함유 하이드로겔 조성물 및 이의 제조방법 |
| JP2024539956A (ja) | 2021-10-29 | 2024-10-31 | スリングショット バイオサイエンシーズ, インコーポレイテッド | フィーダー細胞としておよび合成抗原提示細胞としてのヒドロゲル粒子 |
| DK4452267T3 (da) * | 2021-12-23 | 2025-05-26 | Cilcare Dev | 4-phenyl-tetrahydropyridinderivater til behandling af hørelidelser |
| CA3243960A1 (en) * | 2022-02-09 | 2023-08-17 | Interlude Biopharma Co. | RHO KINASE INHIBITION COMPOSITIONS AND METHODS |
| AU2023265684A1 (en) | 2022-05-05 | 2024-11-21 | Slingshot Biosciences, Inc. | Engineered particles as red blood cell mimics and compositions containing same for hematology |
| WO2023230430A1 (en) * | 2022-05-21 | 2023-11-30 | Neuvision Development Llc | Topical ocular administration of ambroxol for ocular pain |
| CA3257621A1 (en) | 2022-06-02 | 2023-12-07 | Slingshot Biosciences, Inc. | APOPTOTIC CELL MIMETIC |
| EP4299059A1 (en) | 2022-07-01 | 2024-01-03 | Labelic Analysis, S.L. | Composition for the treatment of tinnitus |
| EP4316462A1 (en) * | 2022-08-05 | 2024-02-07 | Dompé farmaceutici S.p.a. | Intranasal administration of bdnf for the treatment of sensorineural hearing loss |
| CN115317446A (zh) * | 2022-09-01 | 2022-11-11 | 黑龙江迪龙制药有限公司 | 一种含有天麻素的复方制剂及其制备方法 |
| WO2024092161A2 (en) | 2022-10-26 | 2024-05-02 | Slingshot Biosciences, Inc. | Size-tunable synthetic particles with tunable optical properties and methods for using the same for immune cell activation |
| WO2024148287A2 (en) * | 2023-01-06 | 2024-07-11 | Gateway Biotechnology, Inc. | Combination therapies for treatment of hearing disorders |
| CN116019818B (zh) * | 2023-01-18 | 2024-03-19 | 上海交通大学医学院附属第九人民医院 | 一种用于预防、改善和/或治疗耳蜗突触损伤的组合物及其应用 |
| US12461007B2 (en) | 2023-08-29 | 2025-11-04 | Slingshot Biosciences, Inc. | CD34 stem cell mimics |
| CN117448350B (zh) * | 2023-10-18 | 2024-05-10 | 哈尔滨学院 | 一种利用桑黄Pb-bHLH9基因提高酿酒酵母多重胁迫抗性的应用 |
| CN117860771B (zh) * | 2024-01-15 | 2026-07-28 | 山东第一医科大学(山东省医学科学院) | 黄豆苷在制备抗顺铂耳毒性药物中的应用 |
| CN121891373B (zh) * | 2026-03-24 | 2026-07-10 | 山东大学齐鲁医院 | 尼可霉素在制备治疗脂质沉积性肌病的药物中的应用 |
Family Cites Families (189)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| DE2010115A1 (de) | 1970-03-04 | 1971-09-16 | Farbenfabriken Bayer Ag, 5090 Leverkusen | Verfahren zur Herstellung von Mikrogranulaten |
| US4188373A (en) | 1976-02-26 | 1980-02-12 | Cooper Laboratories, Inc. | Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes |
| US4389330A (en) | 1980-10-06 | 1983-06-21 | Stolle Research And Development Corporation | Microencapsulation process |
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| US4474572A (en) | 1981-09-29 | 1984-10-02 | Syntex (U.S.A.) Inc. | Implanting device and implant magazine |
| US4530840A (en) | 1982-07-29 | 1985-07-23 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
| US4478822A (en) | 1983-05-16 | 1984-10-23 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
| US4968507A (en) * | 1984-06-20 | 1990-11-06 | Merck & Co., Inc. | Controlled porosity osmotic pump |
| US4758435A (en) | 1986-08-11 | 1988-07-19 | American Cyanamid Company | Estradiol implant composition and method for preparation |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US4900552A (en) | 1988-03-30 | 1990-02-13 | Watson Laboratories, Inc. | Mucoadhesive buccal dosage forms |
| US5702716A (en) | 1988-10-03 | 1997-12-30 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
| US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
| US6436425B1 (en) | 1988-11-16 | 2002-08-20 | Mdv Technologies, Inc. | Method and non-gelling composition for inhibiting post-surgical adhesions |
| US5324519A (en) | 1989-07-24 | 1994-06-28 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
| AU6952391A (en) | 1989-11-29 | 1991-06-26 | Brigham And Women's Hospital | (ala il-8)77 as a leukocyte adhesion inhibitor |
| US5292516A (en) | 1990-05-01 | 1994-03-08 | Mediventures, Inc. | Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers |
| US6221367B1 (en) | 1992-06-15 | 2001-04-24 | Emisphere Technologies, Inc. | Active agent transport systems |
| US5714167A (en) | 1992-06-15 | 1998-02-03 | Emisphere Technologies, Inc. | Active agent transport systems |
| IT1251151B (it) | 1991-08-05 | 1995-05-04 | Fidia Spa | Materiale spugnoso essenzialmente costituito da acido ialuronico,o suoi derivati |
| EP0551626A1 (en) | 1991-12-19 | 1993-07-21 | LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. | Thermoreversible gel as a liquid pharmaceutical carrier for a galenic formulation |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| US6083354A (en) | 1992-07-24 | 2000-07-04 | Matsushita Electric Industrial Co., Ltd. | Treatment method for diamonds |
| US5981719A (en) | 1993-03-09 | 1999-11-09 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
| ES2113094T3 (es) | 1993-03-09 | 1998-04-16 | Epic Therapeutics Inc | Las microparticulas macromoleculares y metodos de obtencion. |
| US6090925A (en) | 1993-03-09 | 2000-07-18 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
| AU7376494A (en) * | 1993-08-04 | 1995-02-28 | Andrulis Pharmaceuticals Corporation | Treatment of rheumatoid arthritis with thalidomide alone or in combination with other anti-inflammatory agents |
| US5421818A (en) | 1993-10-18 | 1995-06-06 | Inner Ear Medical Delivery Systems, Inc. | Multi-functional inner ear treatment and diagnostic system |
| EP1125577B1 (en) | 1994-04-08 | 2006-02-15 | QLT USA, Inc. | Liquid drug delivery compositions |
| TW438601B (en) | 1994-05-18 | 2001-06-07 | Janssen Pharmaceutica Nv | New mucoadhesive emulsion compositions and a process for the preparation thereof |
| AU698393B2 (en) | 1994-06-24 | 1998-10-29 | Immunex Corporation | Controlled release polypeptide compositions and methods of treating inflammatory bowel disease |
| GB9505032D0 (en) | 1995-03-13 | 1995-05-03 | Westminster Lab Ltd | Improvements in or relating to organic compositions |
| IL112834A (en) | 1995-03-01 | 2000-12-06 | Yeda Res & Dev | Pharmaceutical compositions for controlled release of soluble receptors |
| WO1997005185A2 (en) * | 1995-07-28 | 1997-02-13 | Focal, Inc. | Multiblock biodegradable hydrogels for use as controlled release agents for drugs delivery and tissue treatment agents |
| FR2742357B1 (fr) | 1995-12-19 | 1998-01-09 | Rhone Poulenc Rorer Sa | Nanoparticules stabilisees et filtrables dans des conditions steriles |
| FR2742750B1 (fr) | 1995-12-22 | 1998-01-30 | Oreal | Nouveaux derives de l'acide l-2-oxothiazolidine 4-carboxylique et leur utilisation pour le soin de la peau |
| US6225282B1 (en) * | 1996-01-05 | 2001-05-01 | Genentech, Inc. | Treatment of hearing impairments |
| US5837681A (en) * | 1996-02-23 | 1998-11-17 | Amgen Inc. | Method for treating sensorineural hearing loss using glial cell line-derived neurotrophic factor (GDNF) protein product |
| US6379911B2 (en) | 1996-02-23 | 2002-04-30 | Albert Einstein College Of Medicine Of Yeshiva University | Enzyme detection/assay method and substrates |
| US5929041A (en) | 1996-02-23 | 1999-07-27 | Amgen Inc. | Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product |
| AU2676397A (en) | 1996-04-18 | 1997-11-07 | University Technology Corporation | Methods for treating middle and inner ear disorders |
| US5861174A (en) | 1996-07-12 | 1999-01-19 | University Technology Corporation | Temperature sensitive gel for sustained delivery of protein drugs |
| US6156728A (en) * | 1996-11-01 | 2000-12-05 | Genentech, Inc. | Treatment of inner ear hair cells |
| US5945126A (en) | 1997-02-13 | 1999-08-31 | Oakwood Laboratories L.L.C. | Continuous microsphere process |
| US5939421A (en) | 1997-07-01 | 1999-08-17 | Signal Pharmaceuticals, Inc. | Quinazoline analogs and related compounds and methods for treating inflammatory conditions |
| US6043221A (en) | 1997-07-30 | 2000-03-28 | Amgen Inc. | Method for preventing and treating hearing loss using a neuturin protein product |
| DE69833000T2 (de) | 1997-09-26 | 2006-09-07 | Noven Pharmaceuticals, Inc., Miami | Bio-klebemittelzusammensetzungen |
| US6004573A (en) | 1997-10-03 | 1999-12-21 | Macromed, Inc. | Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties |
| US6117949A (en) | 1998-10-01 | 2000-09-12 | Macromed, Inc. | Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties |
| US6201072B1 (en) | 1997-10-03 | 2001-03-13 | Macromed, Inc. | Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties |
| US5985848A (en) | 1997-10-14 | 1999-11-16 | Albert Einstein College Of Medicine Of Yeshiva University | Inhibitors of nucleoside metabolism |
| KR20010031363A (ko) | 1997-10-22 | 2001-04-16 | 젠스 포니카우 | 진균류에 의한 점막염을 국소 치료하기 위한 항진균제의용도 |
| DE19748763A1 (de) | 1997-11-05 | 1999-05-06 | Hans Peter Zenner | Verwendung von Vasopressin-Antagonisten |
| SE9704186D0 (sv) | 1997-11-14 | 1997-11-14 | Astra Ab | New composition of matter |
| US6649621B2 (en) | 1997-12-16 | 2003-11-18 | The United States Of America As Represented By The Secretary Of The Navy | Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms |
| US6177434B1 (en) | 1997-12-16 | 2001-01-23 | The United States Of America As Represented By The Secretary Of The Navy | Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms |
| GB9812426D0 (en) | 1998-06-10 | 1998-08-05 | Reckitt & Colmann Prod Ltd | Improvements in or relating to organic compositions |
| WO2000007603A2 (en) | 1998-08-04 | 2000-02-17 | Madash Llp | End modified thermal responsive hydrogels |
| US6319513B1 (en) | 1998-08-24 | 2001-11-20 | The Procter & Gamble Company | Oral liquid mucoadhesive compounds |
| US20020009478A1 (en) | 1998-08-24 | 2002-01-24 | Douglas Joseph Dobrozsi | Oral liquid mucoadhesive compositions |
| EP1107791B8 (en) | 1998-09-04 | 2007-11-07 | Scios Inc. | Hydrogel compositions for the controlled release administration of growth factors |
| US6740664B2 (en) | 1998-09-30 | 2004-05-25 | Alcon, Inc. | Methods for treating otic and ophthalmic infections |
| US6270802B1 (en) | 1998-10-28 | 2001-08-07 | Oakwood Laboratories L.L.C. | Method and apparatus for formulating microspheres and microcapsules |
| US8197461B1 (en) | 1998-12-04 | 2012-06-12 | Durect Corporation | Controlled release system for delivering therapeutic agents into the inner ear |
| US6451346B1 (en) * | 1998-12-23 | 2002-09-17 | Amgen Inc | Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents |
| JP3572570B2 (ja) | 1999-02-01 | 2004-10-06 | オーテックス株式会社 | カチオン重合性有機物質用の重合開始剤 |
| PT1165564E (pt) | 1999-04-08 | 2009-04-16 | Einstein Coll Med | Processo para a preparação de inibidores do metabolismo de nucleósidos |
| US6287588B1 (en) | 1999-04-29 | 2001-09-11 | Macromed, Inc. | Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof |
| US6537540B1 (en) | 1999-05-28 | 2003-03-25 | Targeted Genetics Corporation | Methods and composition for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders |
| HK1047582B (zh) | 1999-06-23 | 2005-03-04 | 萨诺费-阿文蒂斯德国有限公司 | 取代的苯並咪唑 |
| US20040082509A1 (en) | 1999-10-12 | 2004-04-29 | Christophe Bonny | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| US6458387B1 (en) | 1999-10-18 | 2002-10-01 | Epic Therapeutics, Inc. | Sustained release microspheres |
| DE19951360A1 (de) | 1999-10-26 | 2001-05-03 | Aventis Pharma Gmbh | Substituierte Indole |
| JP4879433B2 (ja) | 2000-01-13 | 2012-02-22 | エミスフェアー・テクノロジーズ・インク | 活性剤を送達するための化合物および組成物 |
| GB0003154D0 (en) | 2000-02-12 | 2000-04-05 | Astrazeneca Uk Ltd | Novel compounds |
| EP1268477B1 (en) | 2000-03-15 | 2010-04-21 | Sanofi-Aventis Deutschland GmbH | Substituted beta-carbolines with ikb-kinase inhibiting activity |
| WO2001072298A1 (en) * | 2000-03-27 | 2001-10-04 | The General Hospital Corporation | Treatments for immune-mediated ear disorders |
| US7758888B2 (en) | 2000-04-21 | 2010-07-20 | Sol-Gel Technologies Ltd. | Composition exhibiting enhanced formulation stability and delivery of topical active ingredients |
| US6589549B2 (en) | 2000-04-27 | 2003-07-08 | Macromed, Incorporated | Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles |
| US7018645B1 (en) | 2000-04-27 | 2006-03-28 | Macromed, Inc. | Mixtures of various triblock polyester polyethylene glycol copolymers having improved gel properties |
| US20020013331A1 (en) | 2000-06-26 | 2002-01-31 | Williams Robert O. | Methods and compositions for treating pain of the mucous membrane |
| US7289110B2 (en) * | 2000-07-17 | 2007-10-30 | Human Messaging Ab | Method and arrangement for identifying and processing commands in digital images, where the user marks the command, for example by encircling it |
| UA81743C2 (uk) | 2000-08-07 | 2008-02-11 | Центокор, Инк. | МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ |
| WO2002018371A1 (en) | 2000-08-29 | 2002-03-07 | Industrial Research Limited | Nucleoside metabolism inhibitors |
| JP4272338B2 (ja) | 2000-09-22 | 2009-06-03 | バイエル アクチェンゲゼルシャフト | ピリジン誘導体 |
| IL145584A0 (en) | 2000-10-02 | 2002-06-30 | Pfizer Prod Inc | Nmda nr2b antagonists for treatment |
| EP1328272A1 (en) | 2000-10-12 | 2003-07-23 | SmithKline Beecham Corporation | Nf-kappa-b inhibitors |
| AU2002211663A1 (en) | 2000-10-12 | 2002-04-22 | Smith Kline Beecham Corporation | Nf-$g(k)b inhibitors |
| CN1503673A (zh) | 2000-10-26 | 2004-06-09 | �㽭�пؼ����ɷ�����˾ | 消炎药 |
| US20040018228A1 (en) * | 2000-11-06 | 2004-01-29 | Afmedica, Inc. | Compositions and methods for reducing scar tissue formation |
| JP2002193938A (ja) | 2000-12-01 | 2002-07-10 | Bayer Ag | 4−アリールピリジン誘導体 |
| US7122544B2 (en) | 2000-12-06 | 2006-10-17 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto |
| EP1370139A4 (en) | 2001-01-04 | 2010-09-22 | Einstein Coll Med | INHIBITORS OF ADP-RIBOSYLTRANSFERASES, CYCLASES AND HYDROLASES AND THEIR USE |
| SE0100158D0 (sv) | 2001-01-19 | 2001-01-19 | Synphora Ab | Novel method and composition for local treatment of Meniere´s disease and tinnitus |
| CZ20032287A3 (cs) | 2001-02-01 | 2004-02-18 | Bristol-Myers Squibb Company | Způsoby léčení zánětlivých a imunitních nemocí za použití inhibitorů IkB kinázy (IKK) |
| US20060269602A1 (en) | 2001-04-13 | 2006-11-30 | Dasch James R | Method of modifying the release profile of sustained release compositions |
| WO2002094265A1 (en) | 2001-05-24 | 2002-11-28 | Leo Pharma A/S | A method of modulating nf-$g(k)b activity |
| US20030045515A1 (en) | 2001-05-24 | 2003-03-06 | Lise Binderup | Combination medicament for treatment of neoplastic diseases |
| SE0102617D0 (sv) | 2001-07-25 | 2001-07-25 | Astrazeneca Ab | Novel compounds |
| TWI324925B (en) | 2001-08-23 | 2010-05-21 | Novartis Ag | Ophthalmic composition |
| CA2460939C (en) | 2001-09-19 | 2008-07-29 | Pharmacia Corporation | Substituted pyrazolyl compounds for the treatment of inflammation |
| EP1444207A2 (en) | 2001-09-19 | 2004-08-11 | Pharmacia Corporation | Substituted pyrazolyl-compounds for the treatment of inflammation |
| US7166639B2 (en) | 2001-10-04 | 2007-01-23 | Smithkline Beecham Corporation | NF-κB inhibitors |
| CA2467854A1 (en) | 2001-11-21 | 2003-06-05 | Vern L. Schramm | Sir2 products and activities |
| US7001615B1 (en) | 2001-12-07 | 2006-02-21 | Alcon, Inc. | Sustained release ophthalmic, otic and nasal suspension |
| MXPA04005427A (es) | 2001-12-10 | 2005-04-19 | Amgen Inc | Ligandos de receptor vainilloide y su uso en tratamientos. |
| RS63204A (sr) | 2002-01-17 | 2006-10-27 | Neurogen Corporation | Supstituisani analozi hinazolin-4-ilamina kao modulatori kapsaicina |
| US20030229333A1 (en) | 2002-02-22 | 2003-12-11 | Control Delivery Systems, Inc. | Methods for treating otic disorders |
| JP2003277383A (ja) | 2002-03-14 | 2003-10-02 | Bayer Ag | 光学活性ピリジン誘導体およびそれを含む医薬 |
| US7098334B2 (en) | 2002-03-25 | 2006-08-29 | Industrial Research Limited | 4-amino-5H-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases |
| JP2005531574A (ja) | 2002-05-22 | 2005-10-20 | アムジエン・インコーポレーテツド | 痛みの治療にバニロイド受容体リガンドとして使用するためのアミノ−ピリジン、−ピリジンおよびピリダジン誘導体 |
| US7022680B2 (en) | 2002-05-30 | 2006-04-04 | Albert Einstein College Of Medicine Of Yeshiva University | Inhibitors of ADP-ribosyl transferases, cyclases, and hydrolases |
| TW200410945A (en) | 2002-08-08 | 2004-07-01 | Amgen Inc | Vanilloid receptor ligands and their use in treatments" |
| US7589110B2 (en) | 2002-09-06 | 2009-09-15 | Durect Corporation | Delivery of modulators of glutamate-mediated neurotransmission to the inner ear |
| US20060013858A1 (en) | 2002-10-29 | 2006-01-19 | Trune Dennis R | Fludrocortisone treatment for hearing loss |
| US7220431B2 (en) * | 2002-11-27 | 2007-05-22 | Regents Of The University Of Minnesota | Methods and compositions for applying pharmacologic agents to the ear |
| US7582635B2 (en) | 2002-12-24 | 2009-09-01 | Purdue Pharma, L.P. | Therapeutic agents useful for treating pain |
| US8802116B2 (en) * | 2003-02-27 | 2014-08-12 | Novasel Australia Pty. Ltd. | Poloxamer emulsion preparations |
| AU2003900887A0 (en) * | 2003-02-27 | 2003-03-13 | Novasel Australia Pty Ltd | Poloxamer emulsion preparations |
| US20040185047A1 (en) | 2003-03-21 | 2004-09-23 | Jill Giles-Komar | Anti- TNF antibodies, compositions, methods and uses |
| US7279499B2 (en) | 2003-04-21 | 2007-10-09 | Eli Lilly And Company | Substituted benzopyrans as selective estrogen receptor-beta agonists |
| ATE337003T1 (de) * | 2003-04-28 | 2006-09-15 | Biofrontera Bioscience Gmbh | Verwendung von riluzole kombiniert mit geeigneten hilfs-und zusatzstoffen zur behandlung von krankheiten, die durch eine hyperproliferation von keratinozyten gekennzeichnet sind, insbesondere neurodermitis und psoriasis |
| US20040247575A1 (en) | 2003-06-03 | 2004-12-09 | Caplice Noel M. | Smooth muscle progenitor cells |
| US7329664B2 (en) | 2003-07-16 | 2008-02-12 | Neurogen Corporation | Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues |
| EP1648878B9 (en) | 2003-07-24 | 2011-03-16 | Euro-Celtique S.A. | Piperidine compounds and pharmaceutical compositions containing them |
| US7390907B2 (en) | 2003-09-30 | 2008-06-24 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| US7700086B2 (en) | 2003-11-06 | 2010-04-20 | Pluromed, Inc. | Internal clamp for surgical procedures |
| US20050137122A1 (en) | 2003-12-17 | 2005-06-23 | Alcon, Inc. | Use of agents that prevent generation of amyloid and amyloid-like lipoproteins, and/or use of agents that promote sequestration and/or degradation of, and/or prevent neurotoxicity of such proteins in the treatment of hearing loss and improving body balance |
| US7312330B2 (en) | 2003-12-24 | 2007-12-25 | Renovis, Inc. | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof |
| TW200530235A (en) | 2003-12-24 | 2005-09-16 | Renovis Inc | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof |
| JP2005220070A (ja) | 2004-02-05 | 2005-08-18 | Medgel Corp | 神経再生および保護のための生体吸収性高分子ハイドロゲル製剤 |
| US20060063802A1 (en) | 2004-03-29 | 2006-03-23 | Matthieu Guitton | Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
| US8268866B2 (en) | 2004-03-29 | 2012-09-18 | Matthieu Guitton | Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
| EP1747215A1 (en) | 2004-05-12 | 2007-01-31 | Aventis Pharmaceuticals, Inc. | Substantially pure 2-{¬2-(2-methylamino-pyrimidin-4-yl)-1h-indole-5-carbonyl|-amino}-3-(phenylpyridin-2-yl-amino)-propionic acid as an ikb kinase inhibitor |
| WO2005115527A2 (en) | 2004-05-24 | 2005-12-08 | Auris Medical, Llc. | Combined otic aspirator and medication dispenser |
| US20060034889A1 (en) | 2004-08-16 | 2006-02-16 | Macromed, Inc. | Biodegradable diblock copolymers having reverse thermal gelation properties and methods of use thereof |
| US20060046970A1 (en) | 2004-08-31 | 2006-03-02 | Insite Vision Incorporated | Topical otic compositions and methods of topical treatment of prevention of otic infections |
| US8498681B2 (en) | 2004-10-05 | 2013-07-30 | Tomophase Corporation | Cross-sectional mapping of spectral absorbance features |
| EA200700807A1 (ru) | 2004-10-05 | 2007-08-31 | Мерц Фарма Гмбх Унд Ко. Кгаа | Новые циклические и ациклические пропеноны для лечения заболеваний цнс |
| US20060105967A1 (en) | 2004-11-18 | 2006-05-18 | Advanced Gene Technology, Corp. | Flavone derivatives as TNFalpha inhibitors or antagonists |
| WO2006076318A1 (en) | 2005-01-12 | 2006-07-20 | Aventis Pharmaceuticals Inc. | Monopotassium salt of an ikb kinase inhibitor |
| AU2006204699B2 (en) | 2005-01-13 | 2012-04-26 | Sirtris Pharmaceuticals, Inc. | Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders |
| CA2593482A1 (en) | 2005-01-14 | 2006-07-20 | Neurogen Corporation | Heteroaryl substituted quinolin-4-ylamine analogues |
| JP2008537684A (ja) | 2005-01-24 | 2008-09-25 | ニューロシステック コーポレイション | 内耳およびその他の組織へ治療薬および/またはその他の薬剤を送達するための装置および方法 |
| AU2006208042A1 (en) | 2005-01-25 | 2006-08-03 | Neurogen Corporation | Substituted pyridazinyl-and pyrimidinyl-quinolin-4-ylamine analogues |
| US20060221197A1 (en) | 2005-03-30 | 2006-10-05 | Jung Edward K | Image transformation estimator of an imaging device |
| US7576099B2 (en) | 2005-02-28 | 2009-08-18 | Renovis, Inc. | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
| TW200719884A (en) | 2005-03-10 | 2007-06-01 | 3M Innovative Properties Co | Methods of treating ear infections |
| EP1858865B1 (en) | 2005-03-10 | 2009-09-16 | Pfizer Inc. | Substituted n-sulfonylaminophenylethyl-2-phenoxy acetamide compounds |
| US7312233B2 (en) | 2005-03-14 | 2007-12-25 | Renovis, Inc. | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
| EA200701745A1 (ru) | 2005-03-17 | 2008-06-30 | Пфайзер, Инк. | Циклопропанкарбоксамидные производные |
| CA2600282A1 (en) | 2005-03-29 | 2006-10-05 | Roehm Gmbh | Multiparticulate pharmaceutical form comprising pellets with a substance having a modular effect in relation to active ingredient release |
| ES2382876T3 (es) | 2005-05-31 | 2012-06-14 | Pfizer, Inc. | Compuestos de ariloxi-N-biciclometil-acetamida sustituidos como antagonistas de VR1 |
| US20070021352A1 (en) * | 2005-07-20 | 2007-01-25 | Cypress Bioscience, Inc. | Prevention and treatment of hearing disorders |
| WO2007031098A1 (en) | 2005-09-12 | 2007-03-22 | Xigen S.A. | Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
| EP1928439A4 (en) | 2005-09-26 | 2009-04-29 | Piedmont Pharmaceuticals Llc | METHOD FOR THE TREATMENT AND PREVENTION OF OTITIS MEDIA WITH CHEMICAL PENETRATION AMPLIFIERS TO FACILITATE THE TRANSMEMBRANOESE DRUG DELIVERY IN THE MIDDLE EAR |
| CN101272807A (zh) | 2005-09-26 | 2008-09-24 | 皮埃蒙特医药品有限公司 | 使用非离子表面活性剂促进跨膜药物输送到中耳治疗和预防中耳炎的方法 |
| CA2620374C (en) | 2005-09-28 | 2012-12-11 | Thomas Meyer | Pharmaceutical compositions for the treatment of inner ear disorders |
| AU2006303037A1 (en) | 2005-10-21 | 2007-04-26 | Merz Pharma Gmbh & Co Kgaa | Chromenones and their use as modulators of metabotropic glutamate receptors |
| US7785834B2 (en) | 2005-11-10 | 2010-08-31 | Ercole Biotech, Inc. | Soluble TNF receptors and their use in treatment of disease |
| US20070110788A1 (en) | 2005-11-14 | 2007-05-17 | Hissong James B | Injectable formulation capable of forming a drug-releasing device |
| US20070178051A1 (en) | 2006-01-27 | 2007-08-02 | Elan Pharma International, Ltd. | Sterilized nanoparticulate glucocorticosteroid formulations |
| JP4273235B2 (ja) * | 2006-06-01 | 2009-06-03 | 国立大学法人 新潟大学 | アクアポリン4阻害薬 |
| TW200819458A (en) | 2006-06-23 | 2008-05-01 | Merz Pharma Gmbh & Co Kgaa | Metabotropic glutamate receptor modulators |
| CL2007001829A1 (es) | 2006-06-23 | 2008-01-25 | Smithkline Beecham Corp | P-toluensulfonato de n-[4-cloro-2-hidroxi-3-(piperazina-1-sulfonil)fenil]-n-(2-cloro-3-fluorofenil)urea;procedimiento de preparacion;composicion farmaceutica;combinacion farmaceutica;y uso en el tratamiento de una enfermedad mediada por la quiimioquina il-8, tales como asma y epoc. |
| US8377898B2 (en) | 2006-10-12 | 2013-02-19 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response |
| WO2008049196A1 (en) | 2006-10-27 | 2008-05-02 | Iomedix Development International Srl | Composition for improving blood cholesterol levels |
| WO2008076556A2 (en) | 2006-11-15 | 2008-06-26 | Massachusetts Eye & Ear Infirmary | Generation of inner ear cells |
| JP2010525073A (ja) | 2007-04-23 | 2010-07-22 | ハウス イアー インスティトゥート | 代謝型グルタミン酸受容体7の調節による老人性難聴の治療及び/又は予防 |
| WO2009132050A2 (en) | 2008-04-21 | 2009-10-29 | Otonomy, Inc. | Auris formulations for treating otic diseases and conditions |
| MY161021A (en) | 2008-05-14 | 2017-03-31 | Otonomy Inc | Controlled release corticosteroid and methods for the treatment of otic disorders |
| WO2009142719A2 (en) | 2008-05-19 | 2009-11-26 | Massachusetts Institute Of Technology | Tympanic membrane permeating ear drops and uses thereof |
| US8648119B2 (en) | 2008-05-23 | 2014-02-11 | Otonomy, Inc. | Controlled release immunomodulator compositions and methods for the treatment of otic disorders |
| CN101288643B (zh) * | 2008-06-17 | 2012-11-14 | 杨喜鸿 | 含有他克莫司的凝胶剂组合物及其制备方法和药物应用 |
| US8846770B2 (en) | 2008-06-18 | 2014-09-30 | Otonomy, Inc. | Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders |
| WO2010011466A2 (en) | 2008-06-27 | 2010-01-28 | Otonomy, Inc. | Controlled-release cns modulating compositions and methods for the treatment of otic disorders |
| US8349353B2 (en) | 2008-06-27 | 2013-01-08 | Otonomy, Inc. | Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders |
| EP2296632A4 (en) | 2008-07-14 | 2014-11-12 | Otonomy Inc | COMPOSITIONS AND METHODS FOR MODULATING CONTROLLED RELEASE APOPTOSIS FOR THE TREATMENT OF OTIC DISORDERS |
| US8784870B2 (en) | 2008-07-21 | 2014-07-22 | Otonomy, Inc. | Controlled release compositions for modulating free-radical induced damage and methods of use thereof |
| WO2010011605A2 (en) | 2008-07-21 | 2010-01-28 | Otonomy, Inc. | Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders |
| US8318817B2 (en) | 2008-07-21 | 2012-11-27 | Otonomy, Inc. | Controlled release antimicrobial compositions and methods for the treatment of otic disorders |
| US8496957B2 (en) | 2008-07-21 | 2013-07-30 | Otonomy, Inc | Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders |
| US8399018B2 (en) | 2008-07-21 | 2013-03-19 | Otonomy, Inc. | Controlled release ion channel modulator compositions and methods for the treatment of otic disorders |
| US20100016450A1 (en) | 2008-07-21 | 2010-01-21 | Otonomy, Inc. | Controlled release delivery devices for the treatment of otic disorders |
| CA2751761A1 (en) | 2008-10-22 | 2010-04-29 | House Ear Institute | Treatment and/or prevention of inner ear conditions by modulation of a metabotropic glutamate receptor |
| JP5376987B2 (ja) | 2009-02-18 | 2013-12-25 | キヤノン株式会社 | レチクルの製造方法、および面形状計測装置 |
| JP6395687B2 (ja) * | 2015-10-16 | 2018-09-26 | 株式会社カプコン | 映像生成方法、映像生成プログラムおよび映像生成装置 |
-
2009
- 2009-04-21 WO PCT/US2009/041320 patent/WO2009132050A2/en not_active Ceased
- 2009-04-21 AU AU2009239429A patent/AU2009239429B2/en not_active Ceased
- 2009-04-21 CA CA2721927A patent/CA2721927C/en not_active Expired - Fee Related
- 2009-04-21 RU RU2010147298/15A patent/RU2499592C2/ru not_active IP Right Cessation
- 2009-04-21 MX MX2010011545A patent/MX2010011545A/es active IP Right Grant
- 2009-04-21 BR BRPI0910850-5A patent/BRPI0910850B1/pt active IP Right Grant
- 2009-04-21 KR KR1020167005563A patent/KR20160029870A/ko not_active Ceased
- 2009-04-21 KR KR1020207009042A patent/KR102340754B1/ko active Active
- 2009-04-21 CN CN200980114124.XA patent/CN102014957B/zh not_active Expired - Fee Related
- 2009-04-21 US US12/427,663 patent/US9132087B2/en not_active Expired - Fee Related
- 2009-04-21 KR KR1020197006299A patent/KR20190026056A/ko not_active Ceased
- 2009-04-21 CN CN201410609757.0A patent/CN104491864A/zh active Pending
- 2009-04-21 KR KR1020137020483A patent/KR20130097813A/ko not_active Ceased
- 2009-04-21 JP JP2011505264A patent/JP2011518195A/ja active Pending
- 2009-04-21 KR KR1020107026019A patent/KR101449785B1/ko not_active Expired - Fee Related
- 2009-04-21 KR KR1020217026035A patent/KR20210107137A/ko not_active Ceased
- 2009-04-21 EP EP09734483.2A patent/EP2278999B1/en active Active
-
2010
- 2010-10-07 IL IL208549A patent/IL208549A/en active IP Right Grant
-
2013
- 2013-12-04 JP JP2013251480A patent/JP6147653B2/ja not_active Expired - Fee Related
-
2015
- 2015-06-19 US US14/745,160 patent/US10272034B2/en not_active Expired - Fee Related
- 2015-10-08 HK HK15109820.0A patent/HK1209055A1/xx unknown
- 2015-11-04 JP JP2015217021A patent/JP6296565B2/ja not_active Expired - Fee Related
-
2016
- 2016-04-14 US US15/099,336 patent/US10751281B2/en active Active
- 2016-04-15 US US15/130,597 patent/US20160228357A1/en not_active Abandoned
-
2017
- 2017-04-06 JP JP2017076319A patent/JP6544535B2/ja active Active
- 2017-04-18 IL IL251768A patent/IL251768B/en unknown
-
2019
- 2019-03-11 JP JP2019044231A patent/JP2019085423A/ja active Pending
- 2019-04-19 US US16/389,213 patent/US11123285B2/en active Active
-
2020
- 2020-03-19 US US16/824,646 patent/US11123286B2/en not_active Expired - Fee Related
- 2020-06-19 JP JP2020106530A patent/JP2020147610A/ja active Pending
-
2021
- 2021-08-18 US US17/405,992 patent/US20220040096A1/en not_active Abandoned
-
2024
- 2024-03-12 US US18/603,065 patent/US20240358634A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017119723A5 (cg-RX-API-DMAC7.html) | ||
| EP2393474B1 (en) | Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration | |
| EP2174650A1 (en) | Modified release emulsions for application to skin or vaginal mucosa | |
| Kim et al. | Natural and synthetic biomaterials for controlled drug delivery | |
| JP3689791B2 (ja) | タキソイドに基づく新規な組成物 | |
| Dai et al. | A novel vehicle for local protein delivery to the inner ear: injectable and biodegradable thermosensitive hydrogel loaded with PLGA nanoparticles | |
| US10052283B2 (en) | Composition for forming pluronic-based hydrogel with improved stability | |
| MX2012007062A (es) | Composición novedosa de hidrogel transdérmico de dexibuprofeno. | |
| JP2025168555A (ja) | 可逆的ゾル-ゲル転移特性が変化された感温性ヒドロゲル組成物及びその用途 | |
| JP2017081901A (ja) | 水中油型乳化組成物 | |
| Yu et al. | Double-controlled release of poorly water-soluble paliperidone palmitate from self-assembled albumin-oleic acid nanoparticles in PLGA in situ forming implant | |
| CN105101962A (zh) | 用于减脂的比马前列素、比马前列素类似物、前列腺酰胺和前列腺素的持续释放 | |
| JPWO2018134953A1 (ja) | ヒドロゲル組成物およびその製造方法 | |
| Wang et al. | A hybrid thermo-sensitive chitosan gel for sustained release of Meloxicam | |
| JPWO2012105485A1 (ja) | 高分子逆ミセルを含む皮膚用組成物およびその製造方法 | |
| Kaur | Deep Eutectic Solvent (DES)–Based Gels: Structure, Properties, and Emerging Pharmaceutical Applications | |
| JP6759203B2 (ja) | 薬物及び他の物質の送達のための経口組成物 | |
| TW202038909A (zh) | 聚合物微胞載體組合物及含藥物之聚合物微胞組合物 | |
| US9408917B2 (en) | Pharmaceutical composition | |
| TW202315609A (zh) | 高濃度維他命c組成物、其配製方法和使維他命c穩定化的方法 | |
| WO2025262036A1 (en) | Method of manufacturing a pharmaceutical composition | |
| RU2659164C1 (ru) | Способ получения гидрогеля поливинилового спирта | |
| RO131197A2 (ro) | Forme farmaceutice semisolide pentru administrare locală conţinând complecşi organometalici ai neodimiului cu liganzi organici de tip meloxicam şi piroxicam | |
| HK1158969B (en) | Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration | |
| HK1187271A (en) | Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration |